Blinatumomab For Injection
for intravenous use Initial U.S. Approval: 2014
Blinatumomab For Injection is “used to treat adults and children with: • B-cell precursor acute lymphoblastic leukemia (ALL)“. BLINCYTO for injection is a “prescription medicine”. It is available in “form and strength” For injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution. BLINCYTO for injection can be obtained in India upon request.
To inquire about the BLINCYTO (blinatumomab) for injection “offer price in India”, “shipping process”, and the “estimated time of availability in India”, please get in touch at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj). with the IPN Delhi healthcare team for further discussion.”
Facts about your medicine
Approval Date: 2014
Proprietary Name: On Request
Active Ingredient(s): Blinatumomab for injection
Dosage Forms And Strengths: For injection: 35 mcg of lyophilized powder in a single-dose vial for reconstitution.
Manufacturer: Amgen Inc
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For Blinatumomab For Injection
Know about product usage and updates
Blinatumomab, sold under the brand name Blincyto, is a biopharmaceutical medication used as a second-line treatment for Philadelphia chromosome-negative relapsed or refractory acute lymphoblastic leukemia. It belongs to a class of constructed monoclonal antibodies, bi-specific T-cell engagers (BiTEs), that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells. In December 2014, it was approved by the US Food and Drug Administration under the accelerated approval program; marketing authorization depended on the outcome of clinical trials that were ongoing at the time of approval.
Who is the supplier of Specialty drug in India?
Indian Pharma Network (IPN) Legitimate consultant and facilitator for Specialty drugs in India. IPN, Delhi can assist you in connecting with prospective distributors, wholesalers, suppliers, and dealers of BLINCYTO (blinatumomab) for injection. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
BLINCYTO (blinatumomab) for injection, for intravenous use Initial U.S. Approval: 2014
Related posts for product review usage
- HIGHLIGHTS OF PRESCRIBING INFORMATION
- Rationale for a Trial of Blinatumomab in MRD-Negative ALL
- Ponatinib/Blinatumomab Combo Shows Promising Efficacy and Safety in Ph+ ALL
- BLINCYTO® (BLINATUMOMAB) ADDED TO CONSOLIDATION CHEMOTHERAPY SIGNIFICANTLY IMPROVES SURVIVAL IN ADULT PATIENTS WITH MEASURABLE RESIDUAL DISEASE-NEGATIVE B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA (B-ALL)
- FDA Approves BLINCYTO® (blinatumomab) To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia In Adults And Children
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa